209 related articles for article (PubMed ID: 36560881)
1. Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma.
Raninga PV; He Y; Datta KK; Lu X; Maheshwari UR; Venkat P; Mayoh C; Gowda H; Kalimutho M; Hooper JD; Khanna KK
Mol Ther; 2023 Mar; 31(3):729-743. PubMed ID: 36560881
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis.
Yan X; Zhang X; Wang L; Zhang R; Pu X; Wu S; Li L; Tong P; Wang J; Meng QH; Jensen VB; Girard L; Minna JD; Roth JA; Swisher SG; Heymach JV; Fang B
Cancer Res; 2019 Jan; 79(1):125-132. PubMed ID: 30401714
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
Kiebala M; Skalska J; Casulo C; Brookes PS; Peterson DR; Hilchey SP; Dai Y; Grant S; Maggirwar SB; Bernstein SH
Exp Hematol; 2015 Feb; 43(2):89-99. PubMed ID: 25448488
[TBL] [Abstract][Full Text] [Related]
6. Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase.
Malin D; Lee Y; Chepikova O; Strekalova E; Carlson A; Cryns VL
Breast Cancer Res Treat; 2021 Dec; 190(3):373-387. PubMed ID: 34553295
[TBL] [Abstract][Full Text] [Related]
7. X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action.
Parsonage D; Sheng F; Hirata K; Debnath A; McKerrow JH; Reed SL; Abagyan R; Poole LB; Podust LM
J Struct Biol; 2016 May; 194(2):180-90. PubMed ID: 26876147
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and structural characterizations of thioredoxin reductase selenoproteins of the parasitic filarial nematodes Brugia malayi and Onchocerca volvulus.
Fata F; Gencheva R; Cheng Q; Lullo R; Ardini M; Silvestri I; Gabriele F; Ippoliti R; Bulman CA; Sakanari JA; Williams DL; Arnér ESJ; Angelucci F
Redox Biol; 2022 May; 51():102278. PubMed ID: 35276442
[TBL] [Abstract][Full Text] [Related]
9. miR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells.
Li J; Li X; Wu L; Pei M; Li H; Jiang Y
Cell Biol Int; 2019 Aug; 43(8):921-930. PubMed ID: 31115975
[TBL] [Abstract][Full Text] [Related]
10. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2.
Xiao D; Ren P; Su H; Yue M; Xiu R; Hu Y; Liu H; Qing G
Oncotarget; 2015 Dec; 6(38):40655-66. PubMed ID: 26528759
[TBL] [Abstract][Full Text] [Related]
11. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
[TBL] [Abstract][Full Text] [Related]
12. Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.
Tanaka G; Inoue K; Shimizu T; Akimoto K; Kubota K
Cancer Med; 2016 Sep; 5(9):2544-57. PubMed ID: 27485632
[TBL] [Abstract][Full Text] [Related]
13. Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin.
Isakov E; Weisman-Shomer P; Benhar M
Biochim Biophys Acta; 2014 Oct; 1840(10):3153-61. PubMed ID: 25065288
[TBL] [Abstract][Full Text] [Related]
14. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
15. Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells.
Abdalbari FH; Martinez-Jaramillo E; Forgie BN; Tran E; Zorychta E; Goyeneche AA; Sabri S; Telleria CM
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958311
[TBL] [Abstract][Full Text] [Related]
16. Potential Anticancer Activity of Auranofin.
Onodera T; Momose I; Kawada M
Chem Pharm Bull (Tokyo); 2019; 67(3):186-191. PubMed ID: 30827998
[TBL] [Abstract][Full Text] [Related]
17. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
[TBL] [Abstract][Full Text] [Related]
18. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
Roh JL; Jang H; Kim EH; Shin D
Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 deficiency increases the sensitivity of ovarian cancer cells to auranofin.
Oommen D; Yiannakis D; Jha AN
Mutat Res; 2016; 784-785():8-15. PubMed ID: 26731315
[TBL] [Abstract][Full Text] [Related]
20. Expression of the thioredoxin system in an in vivo-like cancer cell environment upon auranofin treatment.
Bhatia M; Lovitt CJ; Raninga PV; Avery VM; Di Trapani G; Tonissen KF
Eur J Cell Biol; 2016 Oct; 95(10):378-388. PubMed ID: 27567536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
